The Noxopharm clinical drug candidate Veyonda® is being investigated for activity against various forms of cancer, via three trials.
These trials aim to prove that adding Veyonda® to standard cancer treatments will enhance the effectiveness of radiotherapy, chemotherapy and immuno-oncology therapy.
External Beam Radiation (DARRT
Immuno-oncology Therapy (IONIC
Veyonda® is currently not approved in Australia or any other country